GANX logo

GANX
Gain Therapeutics Inc

2,626
Mkt Cap
$74.64M
Volume
318,511.00
52W High
$4.34
52W Low
$1.41
PE Ratio
-2.97
GANX Fundamentals
Price
$1.82
Prev Close
$1.75
Open
$1.78
50D MA
$1.93
Beta
1.24
Avg. Volume
563,811.44
EPS (Annual)
-$0.6115
P/B
5.31
Rev/Employee
$0.00
$86.05
Loading...
Loading...
News
all
press releases
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why...
News Placeholder
More News
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat...
News Placeholder
HC Wainwright Has Positive Estimate for GANX Q1 Earnings
Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for Gain Therapeutics in a research note issued on Monday, March 30th. HC Wainwright...
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results
Gain Therapeutics (NASDAQ:GANX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03...
News Placeholder
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside...
News Placeholder
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday
Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available